Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 12Genitourinary 3Other hematologic neoplasm 2CNS 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Myeloid 1Lymphoid 1Breast 1

Conditions

Glioblastoma 2Gliosarcoma 1

Interventions

Temozolomide 258Radiotherapy 147Bevacizumab 142Etoposide 68Cyclophosphamide 68Carboplatin 66Magnetic Resonance Spectroscopy 58Irinotecan 53Cisplatin 52Vincristine 45Filgrastim 43pembrolizumab 40Radiosurgery 36Nivolumab 36Radiation 34Topotecan 31Doxorubicin 30Specimen Handling 29sargramostim 28Lomustine 27Erlotinib Hydrochloride 27Peripheral Blood Stem Cell Transplantation 25Carmustine 25Thiotepa 24Everolimus 23Chemotherapy, Adjuvant 23Surgical Procedures, Operative 22Isotretinoin 22Ipilimumab 22Melphalan 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × montanide ISA 51 × CNS × Clear all
NCT02455557 2026-03-30

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Roswell Park Cancer Institute

Phase 2 Active not recruiting
66 enrolled 11 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT04013672 2024-08-28

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Case Comprehensive Cancer Center

Phase 2 Completed
41 enrolled 15 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡